<DOC>
	<DOCNO>NCT01629563</DOCNO>
	<brief_summary>This Phase III , multicentre , randomize , double-blind , parallel group , long-term study investigate efficacy safety 5mg 10mg dos PGL4001 treatment uterine myoma . The target population compose pre-menopausal woman symptomatic uterine myoma ( ) characterise heavy bleeding.The main objective study ass sustain efficacy safety long term on-off treatment PGL4001 5 10mg dos uterine bleeding , myoma size , pain quality life .</brief_summary>
	<brief_title>PGL4001 Efficacy Assessment Reduction Symptoms Due Uterine Leiomyomata</brief_title>
	<detailed_description />
	<mesh_term>Leiomyoma</mesh_term>
	<mesh_term>Myofibroma</mesh_term>
	<criteria>Be premenopausal woman 18 50 year inclusive . Have Body Mass Index ( BMI ) ≥ 18 ≤ 40 . Have FSH level ≤ 20 mIU/mL Have excessive uterine bleeding due myoma . Have regular menstrual cycle Have myomatous uterus &lt; 16 week least one myoma ≥ 3 cm diameter . If childbearing potential subject must practice nonhormonal method contraception . Has history current uterine , cervical , ovarian breast cancer . Has history current endometrium atypical hyperplasia adenocarcinoma . Has know severe coagulation disorder . Has history current treatment myoma Selective Progesterone Receptor Modulator ( SPRM ) . Has abnormal hepatic function study entry . Has positive pregnancy test , nurse plan pregnancy course study . Has current ( within twelve month ) problem alcohol drug abuse . Is currently enrol investigational drug device study participate study within last 30 day .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>